Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07225205 · ClinicalTrials.gov registry record · NA

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

A NA study of Bladder Cancer and Cystectomy, sponsored by Johns Hopkins University.

Recruiting
Registry status
NA
Development phase
130
Enrollment target
2
Study locations

NCT07225205: Recruiting NA study of Bladder Cancer and Cystectomy, sponsored by Johns Hopkins University.

NCT07225205 is a NA study of Bladder Cancer and Cystectomy that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 130 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07225205, a NA study of Bladder Cancer and Cystectomy, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
NA
Development phase
130 participants
Enrollment target
2
Study locations

Study Summary

Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an accepted standard practice, is beneficial. This study is a single institution randomized controlled trial where patients who choose to undergo radical cystectomy for bladder cancer will be randomized to an Enhanced Recovery After Surgery (ERAS) protocol with a home IVF program, consisting of 1 liter (L) of crystalloid fluid three times per week for four weeks, or ERAS protocol alone. The primary outcome will be 90-day hospital re-admissions, with secondary outcomes including 30 and 90 day complications.

Primary Outcome

The primary outcome will be 90-day hospital readmissions that are unplanned, including admissions for observation

Interventions

  • OTHER Intravenous fluids
  • OTHER ERAS

Study Locations (2)

Maryland

  • Johns Hopkins Hospital - Baltimore
  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-11-01
Est. Completion 2028-02-01
Phase NA
Johns Hopkins University

1,448 total trials

What NCT07225205 shows while recruiting

NCT07225205 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Intravenous fluids is the first listed.

NCT07225205 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT07225205 about?

NCT07225205 is a clinical study titled "Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy". Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity. Many complications may be driven by dehydration and it is unclear if a home intravenous fluid (IVF) infusion program post-operatively, which is an acce...

What is the current status of trial NCT07225205?

This trial is currently recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2025-11-01. Estimated completion is 2028-02-01.

What conditions does trial NCT07225205 study?

This clinical trial studies the following conditions: Bladder Cancer, Cystectomy, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma.

What interventions are being tested in trial NCT07225205?

The interventions under investigation include: Intravenous fluids (OTHER), ERAS (OTHER).

Who is sponsoring clinical trial NCT07225205?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07225205 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07225205's enrollment target sits among peer trials

130 77th of 175 higher than 99 of 175 other Bladder Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01492036 · 130 participants

    Long-Term Follow-Up of Recipient of Gene Transfer Research

  • NCT01631617 · 130 participants · Phase 2

    Effects of Treatments on Atopic Dermatitis

  • NCT02368041 · 130 participants

    Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure

  • NCT02604277 · 130 participants · NA

    Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07225205, the US trial registry maintained by the National Library of Medicine. NCT07225205 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.